Rino Rappuoli

Rino Rappuoli serves as Chief Scientist and Head External R&D at GSK Vaccines (Siena, Italy) and holds the Professor of Vaccines Research position at the Faculty of Medicine of Imperial College London. His career spans leadership roles at Novartis Vaccines, Chiron Corporation, and Sclavo Research Institute.

• Education: PhD in Biological Sciences (University of Siena); Visiting Scientist at Rockefeller University and Harvard Medical School

Rappuoli's research revolutionized vaccinology through concepts like reverse vaccinology, cellular microbiology, and genetic detoxification. His work spans bacterial pathogenesis, adjuvant development (including MF59), and conjugate vaccine platforms using CRM197.

Key contributions include licensed vaccines for meningococcus C/B and acellular pertussis. The articles reflect his focus on genomic vaccine discovery, aging population immunization, and combating antimicrobial resistance through vaccination. His recent publications emphasize glycoconjugate technologies and global health impact.

• Major Awards: Paul Ehrlich Prize, Albert B. Sabin Medal, Canada Gairdner Award, European Inventor Award, Robert Koch Award, and memberships in NAS, EMBO, and Royal Society

Rappuoli founded the GSK Vaccines Institute for Global Health (GVGH) and has published over 700 peer-reviewed papers. His leadership positions demonstrate both academic and industrial impact.